Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study)).

Next Previous
X
Search
Trial Profile

An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study)).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms SystHERs Registry
  • Sponsors Genentech

    • Most Recent Events

    • 25 Jul 2021 Planned End Date changed from 1 Jun 2020 to 16 Nov 2017.
    • 25 Jul 2021 Planned primary completion date changed from 1 Jun 2020 to 16 Nov 2017.
    • 01 Jul 2021 Results evaluating first-line treatment patterns used in clinical practice; describe variables previously reported to influence treatment choice, including age and race; and report clinical outcomes in patients treated with HP published in the Breast Cancer Research and Treatment
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top